Journal
EXPERT REVIEW OF VACCINES
Volume 15, Issue 4, Pages 497-508Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2016.1128328
Keywords
TDV development; dengue-endemic; live attenuated tetravalent vaccine; safety; Dengue; clinical immunology; dengue-seropositive participants
Categories
Funding
- Inviragen
- Takeda Vaccines, Inc.
- Takeda Vaccines Inc.
Ask authors/readers for more resources
Dengue fever is caused by infection with one of four dengue virus (DENV) serotypes (DENV-1-4), necessitating tetravalent dengue vaccines that can induce protection against all four DENV. Takeda's live attenuated tetravalent dengue vaccine candidate (TDV) comprises an attenuated DENV-2 strain plus chimeric viruses containing the prM and E genes of DENV-1, -3 and -4 cloned into the attenuated DENV-2 'backbone'. In Phase 1 and 2 studies, TDV was well tolerated by children and adults aged 1.5-45years, irrespective of prior dengue exposure; mild injection-site symptoms were the most common adverse events. TDV induced neutralizing antibody responses and seroconversion to all four DENV as well as cross-reactive T cell-mediated responses that may be necessary for broad protection against dengue fever.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available